In this progressing and increasingly competitive commercial landscape, attaining optimal market access is becoming extra challenging for pharmaceutical/medical device patrons. In the stir of the global economic crisis, ever increasing costs and abating healthcare budgets, payers have a significant and growing influence on a product’s commercial success. The need to demonstrate clinical and economic evidence of a product to providers, healthcare decision-makers and payers is becoming the central component to a product’s success.
MarksMan Healthcare Communications is a Health Economic and Outcomes Research (HEOR), Medical Writing and Data Analytics consulting, committed in providing the highest level of scientific evidence to optimize the value and health impact of medicines and health technologies. We offer customised information solutions for all stages of product’s life-cycle and therapeutic categories. We utilize the expertise of our trained professionals to provide accurate, consistent and concise product, disease and therapeutic area information.
Our experienced and trained analytics team provides HEOR, Real Wold Evidence (RWE) and market access support to large and small life science companies. We further provide services pertaining to “Medical Affairs, Data Curation, Patient Chart Abstraction, Data Analytics, Pharmacovigilance and Regulatory Writing”
The policy on “publication of clinical data for medicinal products for human use”, also referred to as the “policy 0070” was launched in 2015 by the European Medicines Agency (EMA), to comply with the growing demand from stakeholders for additional transparency in the clinical data that form the basis of regulatory decisions. (1-3) Policy 0070 […]
The role of the medical affairs (MA) professional is constantly evolving, thanks to ever-increasing advancements and broadening scope of work in the pharmaceutical and healthcare domain. Of late, MA professionals are seen to increasingly get involved in the drug development process in order to manage market access and reimbursement challenges while also facilitating drug discovery, […]
Results from over half of all conducted randomized controlled trials (RCTs), especially those with negative or unfavorable results, never get published. This means, searching only electronic databases that index published literature does not provide the entire spectrum of information; additionally, a bias is induced, since most trials having negative results get omitted. This is extremely […]
Efficacy and Safety of Everolimus as a Combination Therapy in the Treatment of Metastatic Breast Cancer: A Systemic Review and Meta-analysis
Efficacy and Safety of Vedolizumab in the Treatment of Ulcerative Colitis: A Systemic Review and Meta-analysis
Role of Social Media in Patient Reported Outcomes (PRO) Research
Efficacy and Safety of Enzalutamide in Metastatic Prostate Cancer Patients: A Systematic Review and Meta-Analysis
Adaptive Licensing and Real World Evidence (RWE)
A Comparison of AMSTAR and ROBIS tools for Methodological Quality Assessment of Systematic reviews of Alzheimer’s Disease
Medical device manufacturing sector has remained nascent, leading to tremendous import dependency. Lack of domestic manufacturing of medical devices is the main reasons for this import dependency and high cost of medical products and services in the country. To address this situation, Govt. of Andhra Pradesh aims to establish country’s first Andhra Pradesh Medical Technology Zone (AMTZ) at Vishakhapatnam. The goal of this progressive initiative would be to make Andhra Pradesh an internationally recognised manufacturing hub for medical devices, help in national agenda of import substitution, make Andhra Pradesh a leader in medical technology exports, generate employment, and contribute to volume generated cost reduction of medical devices for patients. MarksMan Healthcare is proud to be technology transfer and market research partner with Andhra MedTech Zone, India’s first manufacturing hub for medical devices.
National Health Systems Resource Centre (NHSRC) has been set up under the National Rural Health Mission (NRHM) of Government of India to serve as an apex body for technical assistance.The NHSRC currently consists of eight divisions – Community Processes, Public Health Planning, Human Resources for Health, Quality Improvement in Healthcare, Healthcare Financing, Healthcare Technology, Health Informatics and Public Health Administration. MarksMan Healthcare is empanelled as knowledge partner with the Division of Healthcare Technology, a WHO Collaborating Centre for Priority Medical Devices & Health Technology Policy, that supports technical specifications of medical devices procured under National Health Mission, identification, assessment and uptake of innovations in National Health Programs and supports in health technology systems strengthening and providing technical support to Government’s agenda on improving cost of technologies, safety profile of products.
Kalam Institute of Health Technology (KIHT) aims to facilitate focused research on critical components pertaining to medical devices by supporting institutions involved with R&D, industry, policy makers and knowledge repositories. KIHT broadly functions on Innovation & Market Access, Enabling Technology Transfer, and Research & Development Support. MarksMan Healthcare is empanelled as knowledge partner with the KIHT, also formally inducted as a Joanna Briggs Centre for India for evidence synthesis and technology assessments. KIHT plans to strengthen the HTA programme and opens up avenues for government, academia and private partners in more validated health access avenues in the country, adding another feather to the growing recognition of the MedTech capital of the country acclaimed worldwide. KIHT has also been declared as the regional hub for conducting Health Technology Assessment (HTA) for Department of Health Research, Ministry of Health and Family Welfare.
